Related Experiment Videos
New trends in thromboxane and prostacyclin modulators.
J M Dogné1, X de Leval, J Delarge
1Department of Medicinal Chemistry, University of Liège, 1, av. de l hôpital, tour 4 (+5) Sart-Tilman, Liège, 4000, Belgium. Jean-Michel.Dogne@ulg.ac.be
Current Medicinal Chemistry
|March 7, 2000
Summary
This review covers modulators of thromboxane A2 (TXA2) and prostacyclin (PGI2), focusing on drugs developed to manage diseases involving TXA2 overproduction and PGI2
Area of Science:
- Biochemistry
- Pharmacology
- Cardiovascular Research
Background:
- Thromboxane A2 (TXA2) and prostacyclin (PGI2) are key arachidonic acid metabolites.
- Overproduction of TXA2 contributes to diseases via platelet aggregation and smooth muscle contraction.
- Increased TXA2 is often concurrent with PGI2 stimulation, which counteracts TXA2's effects.
Purpose of the Study:
- To review the development of TXA2 and PGI2 modulators.
- To highlight recent findings on PGI2 and TXA2 modulators in clinical trials or market.
Main Methods:
- Literature review of TXA2 and PGI2 modulators.
- Focus on drugs targeting TXA2/prostaglandin endoperoxide H2 receptor antagonists, thromboxane synthase inhibitors, and PGI2 agonists.
- Analysis of drugs under clinical evaluation or marketed.
Main Results:
- Development of drugs to suppress TXA2 formation and action.
- Exploration of PGI2 agonists to counterbalance TXA2's pathological effects.
- Identification of several modulators in clinical evaluation or on the market.
Conclusions:
- TXA2 and PGI2 modulators represent a significant therapeutic strategy.
- Ongoing research focuses on balancing the effects of TXA2 and PGI2 for disease management.
- Clinical evaluation and market availability of these modulators are advancing treatment options.